dorzolamide hydrochloride and timolol maleate
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE (dorzolamide hydrochloride and timolol maleate) by Novartis is solution, 2%/0. Approved for elevated intraocular pressure (iop) in patients with open-angle glaucoma, ocular hypertension, hypertension and 1 more indications. First approved in 2025.
Drug data last refreshed 18h ago
Solution, 2%/0.5% (preservative free) is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma, by reducing aqueous humor secretion. Elevated intraocular pressure is a…
Worked on DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.